CALT — Calliditas Therapeutics AB Share News
0.000.00%
Last trade - 00:00- $1.10bn
- $1.12bn
- SEK1.21bn
Brief: Japan's Asahi Kasei Corp: To Acquire Sweden's Calliditas Therapeutics AB For Total Equity Value Of About SEK 11.8 Billion (About JPY 174 Billion)
Brief: Calliditas Q1 Sales SEK 295.5 Million vs. IBES Estimate SEK 368 Million
Brief: Calliditas Announces Positive Results Of Phase 2 Head, Neck Cancer Trial With Setanaxib
Brief: Calliditas Announces Positive Nefigard Open Label Extension Results
Brief: Calliditas Receives Notice Of Allowance For US Patent Application
Brief: Calliditas Announces Seven-Year Orphan Drug Exclusivity For Tarpeyo
Travere drug for rare kidney condition recommended for EU approval
Calliditas Therapeutics AB reports results for the quarter ended in December - Earnings Summary
Brief: Calliditas Therapeutics Q4 Operating Income Rises To SEK 41.8 Million
Brief: Calliditas Therapeutics Proposes No Dividend For 2023
Brief: Calliditas Therapeutics Preliminary 2023 Total Revenues At $110-113 Mln
U.S. STOCKS ON THE MOVE-Emeren Group, Delta Airlines, Annexon Inc
U.S. STOCKS ON THE MOVE-CarMax, Spotify, Immunovant
U.S. STOCKS ON THE MOVE-Micron, Boeing, Calliditas Therapeutics
Calliditas surges on US FDA's approval for kidney disease drug
China's Everest Medicines climbs as US FDA approves Nefecon capsules
Brief: Everest Medicines Says Licensing Partner Calliditas Therapeutics Announced U.S. FDA Approved Nefecon Delayed Release Capsules
Calliditas Therapeutics soars on FDA approval of kidney disease drug
US FDA approves Sweden-based Calliditas' kidney disease drug (updated)